NUWE Quote, Financials, Valuation and Earnings

Hologic has a net margin of -158.3% compared to Nuwellis's net margin of -1.73%. Nuwellis's return on equity of -670.55% beat Hologic's return on equity of 11.45%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 2831.48%. On the other hand Hologic has an analysts' consensus of $69.34 which suggests that it could grow by 8.31%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Nuwellis has a beta of 0.281, which suggesting that the stock is 71.882% less volatile than S&P 500. In comparison Hologic has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.736%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $1.9M, which are smaller than Hologic quarterly revenues of $1B. Nuwellis's net income of -$3M is higher than Hologic's net income of -$17.4M. Notably, Nuwellis's price-to-earnings ratio is -- while Hologic's PE ratio is 27.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 2.03x versus 3.70x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -158.3% compared to Nuwellis's net margin of -67.73%. Nuwellis's return on equity of -670.55% beat Quanterix's return on equity of -14.39%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 2831.48%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 98.76%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Nuwellis has a beta of 0.281, which suggesting that the stock is 71.882% less volatile than S&P 500. In comparison Quanterix has a beta of 1.127, suggesting its more volatile than the S&P 500 by 12.667%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $1.9M, which are smaller than Quanterix quarterly revenues of $30.3M. Nuwellis's net income of -$3M is higher than Quanterix's net income of -$20.5M. Notably, Nuwellis's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 2.03x versus 1.63x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Reshape Lifesciences has a net margin of -158.3% compared to Nuwellis's net margin of -68.98%. Nuwellis's return on equity of -670.55% beat Reshape Lifesciences's return on equity of -172.58%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 2831.48%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 51136.69%. Given that Reshape Lifesciences has higher upside potential than Nuwellis, analysts believe Reshape Lifesciences is more attractive than Nuwellis.

Nuwellis has a beta of 0.281, which suggesting that the stock is 71.882% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.59%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $1.9M, which are larger than Reshape Lifesciences quarterly revenues of $1.1M. Nuwellis's net income of -$3M is lower than Reshape Lifesciences's net income of $1.5M. Notably, Nuwellis's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is 0.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 2.03x versus 0.01x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -158.3% compared to Nuwellis's net margin of 3.24%. Nuwellis's return on equity of -670.55% beat Varex Imaging's return on equity of -7.36%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 2831.48%. On the other hand Varex Imaging has an analysts' consensus of $16.60 which suggests that it could grow by 112.82%. Given that Nuwellis has higher upside potential than Varex Imaging, analysts believe Nuwellis is more attractive than Varex Imaging.

Nuwellis has a beta of 0.281, which suggesting that the stock is 71.882% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.263%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $1.9M, which are smaller than Varex Imaging quarterly revenues of $212.9M. Nuwellis's net income of -$3M is lower than Varex Imaging's net income of $6.9M. Notably, Nuwellis's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 2.03x versus 0.41x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.